| Literature DB >> 24594754 |
Belén de la Hera1, Jezabel Varadé1, Marta García-Montojo2, Antonio Alcina3, María Fedetz3, Iraide Alloza4, Ianire Astobiza4, Laura Leyva5, Oscar Fernández6, Guillermo Izquierdo7, Alfredo Antigüedad8, Rafael Arroyo2, Roberto Álvarez-Lafuente2, Koen Vandenbroeck9, Fuencisla Matesanz3, Elena Urcelay1.
Abstract
BACKGROUND: Human endogenous retroviruses (HERVs) are repetitive sequences derived from ancestral germ-line infections by exogenous retroviruses and different HERV families have been integrated in the genome. HERV-Fc1 in chromosome X has been previously associated with multiple sclerosis (MS) in Northern European populations. Additionally, HERV-Fc1 RNA levels of expression have been found increased in plasma of MS patients with active disease. Considering the North-South latitude gradient in MS prevalence, we aimed to evaluate the role of HERV-Fc1on MS risk in three independent Spanish cohorts.Entities:
Mesh:
Year: 2014 PMID: 24594754 PMCID: PMC3971560 DOI: 10.1371/journal.pone.0090182
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic characteristics of the MS patients included in the study.
| Northern Spain | Central Spain | Southern Spain | ||||
|
| Patients | Controls | Patients | Controls | Patients | Controls |
| Subjects (n) | 569 | 980 | 883 | 692 | 1021 | 1359 |
| Female (%) | 73 | 46 | 66 | 55 | 68 | 69 |
| HLA DRB1*15:01 (%) | 42 | 25 | 38 | 11 | 38 | 18 |
| Age (yrs) (Mean ± SD) | 42±13 | 44±9 | 45±10 | 42±17 | 44±11 | 44±9 |
| Age at onset (yrs) (Mean ± SD) | 31±10 | _ | 30±9 | _ | 28±11 | _ |
| Clinical form: | ||||||
| RR (n) | 304 | _ | 653 | _ | 798 | _ |
| SP (n) | 66 | _ | 61 | _ | 82 | _ |
| PP (n) | 48 | _ | 61 | _ | 26 | _ |
Genotype frequencies of rs391745 in the Spanish cohorts included in the study.
| MS type | CC | CG | GG | ||
| n (%) | n (%) | n (%) | |||
|
| MS (n = 569) | Total | 25 (4) | 79 (14) | 465 (82) |
| 15:01+ | 16 (7) | 27 (11) | 195 (82) | ||
| 15:01− | 9 (3) | 52 (16) | 270 (81) | ||
| Controls (n = 980) | Total | 63 (6) | 73 (7) | 844 (86) | |
|
| MS (n = 883) | Total | 44 (5) | 125 (14) | 714 (81) |
| 15:01+ | 13 (4) | 41 (13) | 271 (83) | ||
| 15:01− | 26 (5) | 81 (15) | 423 (80) | ||
| Controls (n = 692) | Total | 44 (6) | 80 (12) | 568 (82) | |
|
| MS (n = 1021) | Total | 40 (4) | 130 (13) | 851 (83) |
| 15:01+ | 13 (6) | 31 (13) | 184 (81) | ||
| 15:01− | 13 (4) | 44 (12) | 309 (84) | ||
| Controls (n = 1359) | Total | 71 (5) | 208 (15) | 1080 (80) |
Figure 1Meta-analysis including the studies of HERV-Fc1 association with MS published previously and those performed in the Spanish cohorts.
Forest plot showing the overall data (A) and after eliminating heterogeneity by removing the Southern Spanish cohort (B).
Figure 2Meta-analysis of HERV-Fc1 association studies with bout-onset MS.
Forest plot including all the available cohorts (A), and after eliminating heterogeneity by removing the Southern Spanish cohort (B).
Figure 3Scheme of the HERV-Fc1 position and polymorphisms in the locus.
The figure depicts from top to bottom: Chr X scale; chromosomal position as indicated in B37/gh19 (Position); SNPs genotyped in the IMSGC-WTCCC2 GWAS (GWAS SNPs); statistically significant SNPs with p≤0.05 (Significant SNPs); position of rs391745 (Studied SNP); HERV-Fc1 retrovirus copy position (Virus Position) and common polymorphisms mapping at this locus (Common SNPs).